alexa Immunogenic Decapeptide As A Therapeutic For Melanoma
ISSN: 2161-0703

Journal of Medical Microbiology & Diagnosis
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

JOINT EVENT ON 15th International PHARMACEUTICAL MICROBIOLOGY AND BIOTECHNOLOGY CONFERENCE & 10th Annual MEDICAL MICROBIOLOGY SUMMIT & EXPO
June 21-23, 2017 London, UK

Navnit Kumar Mishra
M M University, India
Posters & Accepted Abstracts: J Med Microb Diagn
DOI: 10.4172/2161-0703-C1-006
Abstract
Melanoma is a cancer associated with melanin forming cells known as melanocytes of epidermis. The malignant melanoma is increasing at alarming rate worldwide because of ozone layer depletion. Hence, there is an urgent need of the scientists from multidisciplinary areas to targeting the immunological receptors coupled with melanoma. In the present study a mutated decapeptide with ELAGIGILTV epitope has been taken from the melanoma antigen recognized by Programmed Death Receptor (PD-1) of the T-lymphocytes. In general the T-lymphocytes recognize the tumor cells and destroy them. However, the cancer cells protect themselves by Programmed Death Ligand-1 (PD-L-1) present on their surface which interacts to Programmed Death Receptor of the T-lymphocyte by this interaction they overcome the immuno surveillance mechanism. The proposed novel immunogenic decapeptide can block PD-1 receptors of the T lymphocytes and prevent the PD-L-1 binding as well. Lymphocytes once freed from their blindness by the peptide, regain their defense potential by recognizing and destroying cancer cells. Targeting this mechanism of interaction through epitope may act as a therapeutic for the melanoma. Molecular dynamics and molecular docking were the techniques applied to explore the physiochemical properties associated with immunogenicity of the epitope to the receptors. Furthermore this immunogenic epitope can be developed as a vaccine for cancer treatment. Moreover, the potency of bioactive nanoparticle in nanomedicine is well known. Therefore engineering this epitope with bioactive nanoparticle adjuvant could substantially improve the efficacy of the designed vaccine.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords